Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 210.00K | 2.47B | 512.50K | 0.00 | Gross Profit |
-15.00K | 0.00 | 49.00K | 2.47B | 127.50K | -90.16K | EBIT |
-13.61M | -13.83M | -11.01M | -13.88M | -13.14M | -9.98M | EBITDA |
-13.60M | -12.66M | -10.96M | -13.73M | -13.08M | -10.00M | Net Income Common Stockholders |
-12.48M | -12.55M | -9.81M | -13.49M | -12.95M | -10.13M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
17.25M | 19.92M | 23.84M | 29.69M | 35.73M | 9.06M | Total Assets |
18.91M | 21.59M | 25.52M | 30.41M | 36.26M | 9.45M | Total Debt |
230.00K | 232.00K | 175.00K | 221.00K | 259.48K | 55.20K | Net Debt |
-823.00K | -1.04M | -740.00K | -12.14M | -28.87M | -6.36M | Total Liabilities |
2.19M | 2.70M | 2.15M | 2.21M | 1.49M | 1.19M | Stockholders Equity |
17.85M | 20.00M | 24.34M | 29.05M | 35.44M | 8.76M |
Cash Flow | Free Cash Flow | ||||
-7.93M | -7.33M | -6.21M | -6.49M | -4.94M | -6.19M | Operating Cash Flow |
-7.93M | -7.33M | -6.21M | -6.49M | -4.94M | -6.18M | Investing Cash Flow |
6.85M | 4.28M | -5.60M | -10.73M | -3.92M | -305.79K | Financing Cash Flow |
1.14M | 3.42M | 366.00K | 452.00K | 31.57M | 9.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
49 Neutral | $112.42M | ― | -61.14% | ― | -100.00% | -24.28% | |
44 Neutral | $336.29M | ― | -2159.50% | ― | ― | 14.39% | |
42 Neutral | $543.37M | ― | -3138.91% | ― | -24.35% | 61.00% | |
42 Neutral | $15.87M | ― | -90.83% | ― | 650.00% | 89.72% | |
38 Underperform | $6.21M | ― | -1949.77% | ― | -89.76% | 80.28% |
Anixa Biosciences, in collaboration with Cleveland Clinic, unveiled promising results from their Phase 1 trial of a breast cancer vaccine aimed at triple-negative breast cancer (TNBC). The vaccine, based on groundbreaking research, showed safety and efficacy in activating immune responses in patients. As they gear up for a Phase 2 study in 2025, the vaccine’s potential to become a preventive measure against aggressive breast cancer offers hope for future treatments and partnerships with major pharmaceutical firms.